Neurological Effects of Mercury Exposure

0 Flares Twitter 0 Facebook 0 Google+ 0 LinkedIn 0 0 Flares ×


According to the U.S. governmental agencies, toxic metals, such as mercury, lead, and cadmium, have been documented to be neurotoxic, each year causing adverse health effects and learning disabilities to millions, especially children and the elderly. The health effects of toxic metals are synergistic with other toxic exposures, such as pesticides and endocrine disrupting substances, including organochlorine compounds and PCBs. A weakened immune system, often the effect of toxic exposure, may also be more susceptible to various types of parasites, bacteria, and viruses. Studies have found considerable genetic variability in susceptibility to toxic metals. While there is considerable commonality to the health effects commonly caused by these toxic metals and effects are cumulative and synergistic in many cases, this paper will concentrate on the health effects of elemental mercury from amalgam fillings.

Mercury amalgam dental fillings have been found to be the largest source of both inorganic and methylmercury in most who have several amalgam fillings. Those with several amalgam fillings have been found by thousands of medical lab tests to have mercury exposure levels approximately ten times the average level of those without amalgam; saliva and excretion levels decline 90% after amalgam replacement. Clinical experience has identified some of the factors that cause mercury to accumulate in various areas of the body. These include past physical trauma to an area, inflammation, food allergies, geopathic stress, scars, dental trauma, structural abnormalities, biochemical deficiencies, environmental toxicity, and unresolved psychological problems.

Neurological Effects of Mercury and Toxic Metals

Based on numerous studies, toxic metal exposure has the following effects on the human body:

  • kills or damages brain cells and nerve cells (neurotoxin),
  • generates high levels of reactive oxygen species and oxidative stress,
  • depletes glutathione and thiols, causing increased neurotoxicity from interactions of ROS, glutamate, and dopamine,
  • kills or inhibits production brain tubulin cells,
  • inhibits production of neurotransmitters by inhibiting calcium-dependent neurotransmitter release, dihydroteridine reductase, nitric oxide synthase
  • blocks neurotransmitter amino acids,
  • causes abnormal migration of neurons in the cerebral cortex, and
  • affects phenylalanine, serotonin, tyrosine and tryptophan transport to neurons.

In addition, mercury, lead, cadmium, etc. replace essential minerals such as zinc at their sites in enzymes, disabling the necessary enzymatic processes. While there have been large increases of most neurological and immune conditions among adults over the last two decades, the incidence of neurotoxic or immune reactive conditions in infants, such as autism, schizophrenia, ADD, dyslexia, and learning disabilities, have been increasing especially rapidly in recent years. A report by the National Research Council found that 50% of all pregnancies in the U.S. resulted in prenatal or postnatal mortality, significant birth defects, developmental neurological or immune conditions, or otherwise chronically unhealthy babies.

Exposure to toxic chemicals or environmental factors appear to be a factor in as much as 28% of the four million children born each year, with one in six having one of the neurological conditions previously listed. EPA estimates that over three million of these conditions are related to lead or mercury toxicity, with approximately 25% of U.S. infants receiving dangerous levels of mercury exposure. A study found that prenatal Hg exposure is correlated with lower scores in neurodevelopmental screening, but more so in the linguistic pathway. A study at the U.S. CDC found “statistically significant associations” between certain neurologic developmental disorders, such as attention deficit disorder (ADD) and autism, and exposure to mercury from vaccines containing thimerosal before the age of six months. A follow-up on the study, using federal vaccine data bases, confirmed that autism, speaking disorders, and heart arrest have increased exponentially with increasing exposures to thimerosal-containing vaccines. Thimerosal has also been found to have hormonal effects. Prenatal exposure to mercury has also been found to predispose animals and infants to seizures and epilepsy. There is evidence supporting a link between the aluminum hydroxide used in vaccines and brain inflammation, symptoms associated with Parkinson’s, amyotrophic lateral sclerosis (Lou Gehrig’s disease), and Alzheimer’s. Brain inflammation has also been found to be a factor in autism.

A large epidemiological study, NHANES III, by the National Institute for Health found a significant correlation between several chronic health conditions and having more than average number of dental amalgam surfaces. The study observed that patients who had several dental amalgam surfaces were more likely to have a chronic condition; the most commonly correlated diseases to toxic metal exposure includes MS, epilepsy, migraines, mental disorders, diseases of the nervous system, disorders of the thyroid gland, cancers, and infectious diseases. Other conditions where incidence was significantly correlated with having more than the average number of amalgam surfaces are diseases of the male and female genital tracts, disorders of the peripheral nervous system, diseases of the respiratory system, and diseases of the genitourinary system. There has been a huge increase in the incidence of degenerative neurological conditions in virtually all Western countries over the last 2 decades. The increase in Alzheimer’s has been over 300%, while the increase in Parkinson’s and other motor neuron disease has been over 50%. The primary cause appears to be increased exposures to toxic pollutants.

Oxidative stress and reactive oxygen species have been implicated as major factors in neurological disorders including stroke, PD, MS, Alzheimer’s, MND, FM, CFS, etc. Mercury-induced lipid peroxidation has been found to be a major factor in mercury’s neurotoxicity, along with leading to decreased levels of glutathione peroxidation and superoxide dismutase (SOD). Metalloprotein (MT) is involved in metals transport and detoxification. Mercury inhibits sulfur ligands in MT and in the case of intestinal cell membranes inactivates MT, which normally binds cuprous ions, thus allowing buildup of copper to toxic levels in many and malfunction of the Zn/Cu SOD function. Exposure to mercury results in changes in metalloprotein compounds that have genetic effects, having both structural and catalytic effects on gene expression. Some of the processes affected by such MT control of genes include cellular respiration, metabolism, enzymatic processes, metal-specific homeostasis, and adrenal stress response systems. Significant physiological changes occur when metal ion concentrations exceed threshold levels. Such MT formation also appears to have a relation to autoimmune reactions in significant numbers of people. In a population of over 3000 tested by the immune lymphocyte reactivity test (MELISA), 22% tested positive for inorganic mercury and 8% for methylmercury.

Programmed cell death (apoptosis) is documented to be a major factor in degenerative neurological conditions like ALS, Alzheimer’s, MS, Parkinson’s, etc. Some of the factors documented to be involved in apoptosis of neurons and immune cells include inducement of the inflammatory cytokine Tumor Necrosis Factor-alpha (TNFa), reactive oxygen species and oxidative stress, reduced glutathione levels, inhibition of protein kinase C, nitric oxide and peroxynitrite toxicity, excitotoxicity, excess free cysteine levels, excess glutamate toxicity, excess dopamine toxicity, beta-amyloid generation, increased calcium influx toxicity, DNA fragmentation, and mitochondrial membrane dysfunction. Mitochondrial DNA mutations or damage are important to aging and degenerative diseases, and mercury is common cause of mitochondrial DNA damage and degeneration. Pyrroloquinoline Quinone (PPQ), an essential micronutrient, has been found to improve such damage.

TNFa is a cytokine that controls a wide range of immune cell response in mammals, including apoptosis. This process is involved in inflammatory and degenerative neurological conditions like ALS, MS, Parkinson’s, rheumatoid arthritis, etc. Cell signaling mechanisms like sphingolipids are part of the control mechanism for the TNFa apoptosis mechanism. Glutathione is an amino acid that is a normal cellular mechanism for controlling apoptosis. When glutathione is depleted in the brain, reactive oxidative species increased, and CNS and cell signaling mechanisms are disrupted by toxic exposures, resulting in neuronal cell apoptosis and neurological damage. Mercury has been shown to induce TNFa and deplete glutathione, causing inflammatory effects and cellular apoptosis in neuronal and immune cells.

Another neurological effect of mercury that occurs at very low levels is inhibition of nerve growth factors, for which deficiencies result in nerve degeneration. Mercury vapor is lipid soluble and has an affinity for red blood cells and CNS cells. Only a few micrograms of mercury are needed to severely disturb cellular function and inhibit nerve growth. Prenatal or neonatal exposures have been found to have life-long effects on nerve function and susceptibility to toxic effects. Prenatal mercury vapor exposure that results in levels of only four parts per billion in newborn rat brains was found to cause decreases in nerve growth factor and have other affects. This is a level that is common in the population with several amalgam fillings or other exposures. Insulin-like-growth factor I (IGF-I) is positively correlated with growth hormone levels and has been found to be the best easily measured marker for levels of growth hormone, but males have been found more responsive to this factor than women. IGF-I controls the survival of spinal motor neurons affected in ALS during development as well as later in life.

Several clinical trials have found that IGF-I treatment is effective at reducing the damage and slowing the progression of ALS and Alzheimer’s with no medically important adverse effects. It has also been found that in chronically ill patients the levels of pituitary and thyroid hormones that control many bodily processes are low, and that supplementing both the thyrotropin-releasing hormone and the growth control hormone is more effective at increasing all of these hormone levels in the patient.

Mercury can cause depression and mood disorders through increased neurological problems related to lowered levels of neurotransmitters dopamine, serotonin, norepinephrine, and acetylcholinesterase. In such cases, mercury has been found to accumulate in and affect the function of the brain limbic system. The reduced neurotransmitter levels in those with amalgams appear to be a factor that encourages smoking because nicotine increases neurotransmitter levels, and a much higher percentage of those with amalgams smoke than those without amalgams.

Some of the effect on depression is related to mercury’s effect on reducing the level of posterior pituitary hormone (oxytocin). Low levels of pituitary function are associated with depression and suicidal thoughts and appear to be a major factor in suicide of teenagers and other vulnerable groups. The pituitary glands of a group of dentists had 800 times more mercury than controls. This may explain why dentists have much higher levels of emotional problems, depression, suicide, etc. Amalgam fillings as well as nickel and gold crowns are major factors in reducing pituitary function. Supplementary oxytocin extract has been found to alleviate many of these mood problems, along with replacement of metals in the mouth. The normalization of pituitary function often normalizes menstrual cycle problems, endometriosis, and increases fertility.

Animal studies of developmental effects of mercury on the brain have found significant effects at extremely low exposure levels—levels commonly seen in those with amalgam fillings or in dental staff working with amalgam. One study found prenatal mercury vapor exposure decreased NGF concentration in newborn rat’s forebrain at four parts per billion (ppb) tissue concentration.
Another study found general toxicity effects at one micromole (uM) level in immature cell cultures, increased immune-reactivity for glial fibrillary protein at 1 nanamole (0.2 ppb) concentration and microglial response at even lower levels. Other studies on rodents and monkeys found brain cellular migration disturbances, behavioral changes, along with reduced learning and adaption capacity after low levels of mercury vapor exposure. The exposure levels in these studies are seen in the fetus and newborn babies of mother’s with amalgam fillings or who had work involving amalgam during pregnancy. Mercury vapor has been found to primarily affect the central nervous system, while methylmercury primarily affects the peripheral nervous system.

Long-term occupational exposure to low levels of mercury can induce slight cognitive deficits, fatigue, decreased stress tolerance, etc. Higher levels have been found to cause more serious neurological problems. Other studies found that workers exposed at high levels at least 20 years previous had urine peak levels above 600 ug/L, demonstrated significantly decreased strength, decreased coordination, increased tremor, paresthesia, decreased sensation, polyneuropathy, etc. Significant correlations between increasing urine mercury concentrations and prolonged motor and sensory distal latencies were established. Elemental mercury can affect both motor and sensory peripheral nerve conduction, and the degree of involvement is related to time-integrated urine mercury concentrations. 30% of dentists with more than average exposure were found to have neuropathies and visio-graphic dysfunction, compared to none in the control group. Other studies have also found a connection between mercury with peripheral neuropathy and paresthesia.

Chronic mercury exposure has been found to be a significant factor in many neurological conditions including Alzheimer’s, dementia, Parkinson’s, MS, etc. Neurological problems are among the most common and serious problems caused by mercury and include memory loss, moodiness, depression, anger and sudden burst of anger/rage/violence, self-effacement, suicidal thoughts, lack of strength to resolve doubts or resist obsessions or compulsions, etc.
Many studies of patients with major neurological diseases have found evidence amalgam fillings may play a major role in development of conditions such as depression, schizophrenia, bipolar disorder, memory problems, and other more serious neurological diseases, such as MS, ALS, Parkinson’s, and Alzheimer’s. A large U.S. CDC study found that those with more amalgam fillings have significantly more chronic health problems, especially neurological problems and cancer.

Some factors that have been documented in depression are low serotonin levels, abnormal glucose tolerance (hypoglycemia), and low folate levels, which mercury has also been found to be a cause of. Occupational exposure to mercury has been documented to cause depression and anxiety. One mechanism by which mercury has been found to be a factor in aggressiveness and violence is its documented inhibition of the brain neurotransmitter acetylcholinesterase. Low serotonin levels and/or hypoglycemia have also been found in the majority of those with impulsive and violent behavior.

Numerous studies have found long-term chronic low doses of mercury cause neurological, memory, behavioral, sleep, hearing, and mood problems. There is also evidence that fetal or infant exposure causes delayed neurotoxicity evidenced in serious effect at middle age. Organic tin compounds formed from amalgam are even more neurotoxic than mercury. Studies of groups of patients with amalgam fillings found significantly more neurological, memory, mood, and behavioral problems than the control groups.

Other studies found that mercury at levels below the current occupational safety limit causes adverse effects on memory at very low exposure levels. More studies found that long-term exposure causes increased micro nuclei in lymphocytes and significantly increased IgE levels at exposures below current safety levels, as well as linked maternal exposure to cognitive delays. Very high levels of mercury are often found in brain/memory areas (e.g., the cerebral cortex and hippocampus) of patients with diseases with memory-related symptoms. Mercury has been found to cause memory loss by inactivating enzymes necessary for brain cell energy production and proper assembly of the protein tubulin into microtubules. DMSO has been found to have some capability to repair such damage.

Treatment of Toxic Related Neurological Conditions

The mechanisms by which mercury causes neurological conditions have been documented, but researchers have also found that people with such conditions commonly recover or have significant improvement after amalgam replacement from conditions including:

  • memory disorders;
  • schizophrenia and bipolar disorder;
  • depression;
  • insomnia;
  • anger;
  • anxiety;
  • mental confusion;
  • neuropathy/paresthesia;
  • MS;
  • ALS;
  • Parkinson’s and muscle tremors;
  • Alzheimer’s;
  • headaches and migraines;
  • epilepsy; and
  • ataxia and balance problems.

Lipoic acid has been found to have protective effects against cerebral ischemic-reperfusion, excitotoxic amino acid (glutamate) brain injury, mitochondrial dysfunction, and diabetic neuropathy. Other antioxidants such as carnosine, Coenzyme Q10, vitamins C and E, ginkgo biloba, pycnogenol, and selenium have also been found protective against degenerative neurological conditions. Several doctors have found thiamin, vitamin B6, inositol, and folic acid supplementation to alleviate peripheral neuropathies, pain, tinnitus, and other neurological conditions. Several studies have documented that lipoic acid (an antioxidant and chelator) resulted in improvement in the majority of diabetes cases it was used for, by improving glucose metabolism, increasing insulin sensitivity, and reducing nerve damage, including in diabetic neuropathy. Properly formulated nutritional treatments have been found to be effective in treating ADHD and depression. Hormonal imbalances, such as from taking birth control pills, can be a factor in causing vitamin B; B6 and riboflavin deficiencies can be factors in migraine headaches. Supplementation has been found to be helpful in such circumstances.

One chelation expert suggests, when chelating with DMPS, one should also supplement with a good multivitamin/multimineral plus vitamin E(400 IU), selenium (200-400 ug), and vitamin C (2 grams or Vit C IV). The expert also finds chlorella beneficial for most and has found other factors that reduce detoxification include:

  • low sodium, calcium, potassium, or selenium levels;
  • low protein in diet or low stomach acid;
  • hormonal problems;
  • low serum cholesterol (carrier);
  • low glutathione or other detox enzymes;
  • kidney problems or damage from mother’s amalgams;
  • constipation or “leaky gut”; and
  • electromagnetic influences (scars, geopathic stress, EMF, and RF waves).


1. Marlowe M, et al. Main and interactive effects of metallic toxins on classroom behavior. J Abnormal Child Psychol. 1985; 13(2): 185-98.

2. Moon C, et al. Main and interactive effect of metallic pollutants on cognitive functioning. Journal of Learning Disabilities. 1985.

3. Pihl RO, et al. Hair element content in learning disabled children. Science. 1977; 198: 204-6.

4. Gowdy JM, et al. Whole blood mercury in mental hospital patients. Am J Psychiatry. 1978; 135(1): 115-7.

5. Klinghardt D. Migraines, Seizures, and Mercury Toxicity. Future Medicine Publishing; 1997.

6. Klinghardt D. A series of fibromyalgia cases treated for heavy metal toxicity: case report and hypothesis. Journal of Orthopaedic Medicine. 2001; 23: 58-59

7. Gerhard I, Monga B, Waldbrenner A, Runnebaum B. Heavy metals and fertility. J of Toxicology and Environmental Health, Part A. 1998; 54(8): 593-611.

8. Gerhard I, Waibel S, Daniel V, Runnebaum B. Impact of heavy metals on hormonal and immunological factors in women with repeated miscarriages. Hum Reprod Update. 1998; 4(3): 301-309.

9. Gerhard I. Ganzheitiche diagnostik un therapie bie infertilitat. Erfahrungsheilkunde. 1993; 42(3): 100-106.

10. Gerhard I, Waldbrenner P, Thuro H, Runnebaum B. Diagnosis of heavy metal loading by the oral DMPS and chewing gum tests. Klinisches Labor. 1992; 38: 404-411.

11. Hussain S, et al. Mercuric chloride-induced reactive oxygen species and its effect on antioxidant enzymes in different regions of rat brain. J Environ Sci Health B. 1997; 32(3): 395-409.

12. Bulat P. Activity of Gpx and SOD in workers occupationally exposed to mercury. Arch Occup Environ Health. 1998; 71: S37-9.

13. Stohs SJ, Bagchi D. Oxidative mechanisms in the toxicity of metal ions. Free Radic Biol Med. 1995; 18(2): 321-36.

14. Jay D. Glutathione inhibits SOD activity of Hg. Arch Inst Cardiol Mex. 1998; 68(6): 457-61.

15. Tan S, et al. Oxidative stress induces programmed cell death in neuronal cells. J Neurochem. 1998; 71(1): 95-105.

16. Matsuda T, Takuma K, Lee E, et al. Apoptosis of astroglial cells. Nippon Yakurigaku Zasshi. 1998; 112(1): 24.

17. Lee YW, Ha MS, Kim YK. Role of reactive oxygen species and glutathione in inorganic mercury-induced injury in human glioma cells. Neurochem Res. 2001; 26(11): 1187-93.

18. Pizzichini M, et al. Influence of amalgam fillings on Hg levels and total antioxidant activity in plasma of healthy donors. Sci Total Environ. 2003; 301(1-3): 43-50.

19. Valko M, Morris H, Cronin MT. Metals, toxicity and oxidative stress. Curr Med Chem. 2005; 12 (10): 1161-208.

20. Hanson M. Amalgam hazards in your teeth. J. Orthomolecular Psychiatry. 1983; 2(3): 194-201.

21. Lorscheider FL, et al. Evaluation of the safety issue of mercury release from amalgam fillings. FASEB J. 1993; 7: 1432-33.

22. Momoi Y, et al. Measurement of galvanic current and electrical potential in extracted human teeth. J Dent Res. 1986; 65(12): 1441-1444.

23. Holland RI. Galvanic currents between gold and amalgam. Scand J Dent Res,. 1980; 88: 269-72.

24. Wang Chen CP, Greener EH. A galvanic study of different amalgams. Journal of Oral Rehabilitation. 1977; 4: 23-7.

25. Lemons JE, et al. Intraoral corrosion resulting from coupling dental implants and restorative metallic systems. Implant Dent. 1992; 1(2): 107-112.

26. Cohen S. The 24 Hour Pharmacist. Rodale Books; 2007.

27. Goyer RA. Toxic effects of metals. In: Caserett, Doull, ed. Toxicology: The Basic Science of Poisons. New York: McGraw-Hill Inc; 1993.

28. Goodman, Gillman. The Pharmacological Basis of Therapeutics. New York: Mac Millan Publishing Company; 1985.

29. Arena D. Poisoning. 5th ed. Springfield, IL: Charles C. Thomas Publisher; 1986.

30. Hartman DE. Missed diagnoses and misdiagnoses of environmental toxicant exposure, MCS. Psychiatr Clin North Am. 1998; 21(3): 659-70.

31. Haddad, Shannon, Winchester. Clinical Management of Poisoning. 3rd ed. Philadelphia: W. B. Saunders and Company; 1998.

32. Cook TA, et al. Fatal mercury intoxication in a dental surgery assistant. British Dent Journal. 1969; 127: 533-555.

33. Markovich, et al. Heavy metals (Hg, Cd) inhibit the activity of the liver and kidney sulfate transporter Sat-1. Toxicol App Pharmacol. 1999; 154(2): 181-7.

34. McFadden SA. Xenobiotic metabolism and adverse environmental response:
Sulfur-dependent detox pathways. Toxicology. 1996; 111(1-3): 43-65.

35. Langley-Evans SC, et al. SO2: A potent glutathion depleting agent. Comp Biochem Physiol Pharmocol Toxicol Endocrinol. 1996; 114(2): 89-98.

36. Alberti A, Pirrone P, Elia M, Waring RH, Romano C. Sulphation deficit in “low-functioning” autistic children. Biol Psychiatry. 1999; 46(3): 420-4.

37. Henriksson J, Tjalve H. Uptake of inorganic mercury in the olfactory bulbs via olfactory pathways in rats. Environ Res. 1998; 77(2): 130-40.

38. Huggins HA, Levy TE. Uniformed Consent: The Hidden Dangers in Dental Care. Hampton Roads Publishing Company Inc; 1999.

39. Lorscheider FL, et al. Mercury exposure from silver tooth fillings: Emerging evidence questions a paradigm. FASEB J. 1995; 9: 504-508.

40. Ziff S, Ziff M. Infertility and Birth Defects: Is Mercury from Dental Fillings a Hidden Cause? Orlando, FL: Bio-Probe, Inc.; 1987.

41. Inouye M, et al. Behavioral and neuropathological effects of prenatal methyl mercury exposure in mice. Neurobehav. Toxicol. Teratol. 1985; 7: 227-232.

42. Annau Z, et al. Mechanisms of neurotoxicity and their relationships to behavioral changes. Toxicology. 1988; 49(2): 219-25.

43. Vinay SD, Sood PP. Inability of thiol compounds to restore CNS arylsulfatases inhibited by methyl mercury. Pharmacol Toxicol. 1991; 69(1): 71-4.

44. Grandjean P, et al. MeHg and neurotoxicity in children. Am J Epidemiol. 1999; 150(3): 301-5.

45. Budtz-Jorgensen E, Grandjean P, Keiding N, White RF, Weihe P. Benchmark dose calculations of methylmercury-associated neurobehavioral deficits. Toxicol Lett. 2000; 112-113: 193.

46. Crump KS, Kjellstrom T, Shipp AM, Silvers A, Stewart A. Influence of prenatal mercury exposure upon scholastic and psychological test performance: Benchmark analysis of a New Zealand cohort. Risk Analysis. 1998; 18(6): 701-13.

47. Grandjean P, Weihe P, Murata K, Sorensen N, Dahl R, Jorgensen PJ. Cognitive deficit in 7-year-old children with prenatal exposure to methylmercury. Neurotoxicol Teratol. 1997; 19(6): 417-28.

48. More evidence of mercury effects in children. Environ Health Perspect. 1999; 107(11): A554-5.

49. Weihe P, Debes F, White RF, et al. Environmental epidemiology research leads to a decrease of the exposure limit for mercury. Ugeskr Laeger. 2003; 165(2): 107-11.

50. Friese KH. Homoopathische behandlung der amalgamvergiftung. Allg. Homoopathische Z. 1990; 241(5): 184-187.

51. Strassburg M, et al. Generalized allergic reaction from silver amalgam fillings. Dtsche Zahnarztliche Zeit. 1967; 22: 3-9.

52. Knapp LT, Klann E. Superoxide-induced stimulation of protein kinase C via thiol modification and modulation of zinc content. J Biol Chem. 2000.

53. Jenner P. Oxidative mechanisms in PD. Mov Disord. 1998; 13(1): 24-34.

54. Offen D, et al. Antibodies from ALS patients inhibit dopamine release mediated by L-type calcium channels. Neurology. 1998; 51(4):1100-3.

55. Rajanna B, et al. Modulation of protein kinase C by heavy metals. Toxicol Lett. 1995; 81(2-3): 197-203.

56. Badou A, et al. HgCl2-induced IL-4 gene expression in T cells involves a protein kinase C-dependent calcium influx through L-type calcium channels. J Biol Chem. 1997; 272(51): 32411-8.

57. Veprintsev DB. Pb2+ and Hg2+ binding to alpha-lactalbumin. Biochem Mol Biol Int. 1996; 39(6): 1255-65.

58. Arvidson K. Corrosion studies of dental gold alloy in contact with amalgam. Swed. Dent. J. 1984; 68: 135-139.

59. Skinner EW. The Science of Dental Materials. 4th ed. Philadelphia: W. B. Saunders Co.; 1957: 284-285.

60. Schoonover IC, Souder W. Corrosion of dental alloys. JADA. 1941; 28: 1278-91.

61. Kingman A, Albertini T, Brown LJ. Mercury concentrations in urine and blood associated with amalgam exposure in the U.S. military population. J Dent Res. 1998; 77(3): 461-71.

62. Sin YM, Teh WF, Wong MK, Reddy PK. Effect of mercury on glutathione and thyroid hormones. Bull Env Contam Toxicol. 1990; 44(4): 616-622.

63. Kawada J, et al. Effects of inorganic and methylmercury on thyroidal function. J Pharmacobiodyn. 1980; 3(3): 149-59.

64. Ghosh N. Thyrotoxicity of cadmium and mercury. Biomed Environ Sci. 1992; 5(3): 236-40.

65. Goldman, Blackburn. The effect of mercuric chloride on thyroid function of the rat. Toxicol App Pharm. 1979; 48: 49-55.

66. Kabuto M. Chronic effects of methylmercury on the urinary excretion of catecholamines and their responses to hypoglycemic stress. Arch Toxicol. 1991; 65(2): 164-7.

67. Heintze, et al. Methylation of mercury from dental amalgam and mercuric chloride by oral streptococci. Scan. J. Dent. Res. 1983; 91: 150-152.

68. Grasso, Davies. The methylation of mercuric chloride by human intestinal bacteria. Experientia Basel. 1975; 31: 1064-1065.

69. Hamdy MK, et al. Formation of methyl mercury by bacteria. App Microbiol. 1975.

70. Brun A, Abdulla M, Ihse I, Samuelsson B. Uptake and localization of mercury in the brain of rats after prolonged oral feeding with mercuric chloride. Histochemistry. 1976; 47(1): 23-9.

71. Ludwicki JK. Studies on the role of gastrointestinal tract contents in the methylation of inorganic mercury compounds. Bull Env Contam Toxicol. 1989; 42: 283-288.

72. Choi SC, Bartha R. Cobalamin-mediated mercury methylation by desulfovibrio desulfuricans LS. Appl Environ Microbiol. 1993; 59(1): 290-5.

73. Wang J, Liu Z. In vitro Study of strepcoccus mutans in the plaque on the surface of amalgam fillings on the conversion of inorganic mercury to organic mercury. Shanghai Kou Qiang Yi Xue. 2000; 9(2): 70-2.

74. Szasz A, Barna B, Gajda Z, Galbacs G, Kirsch-Volders M, Szente M. Effects of continuous low-dose exposure to organic and inorganic mercury during development on epileptogenicity in rats. Neurotoxicology. 2002; 23(2): 197-206.

75. Nicole A, et al. Direct evidence for glutathione as mediator of apoptosis in neuronal cells. Biomed Pharmacother. 1998; 52(9): 349-55.

76. Spencer JP, et al. Cysteine and GSH in PD: Mechanisms involving ROS. J Neurochem. 1998; 71(5): 2112-22.

77. Bains JS, et al. Neurodegenerative disorders in humans and role of glutathione in oxidative stress mediated neuronal death. Brain Res Rev. 1997; 25(3): 335-58.

78. Medina S, Martinez M, Hernanz A, Antioxidants inhibit the human cortical neuron apoptosis induced by hydrogen peroxide, tumor necrosis factor alpha, dopamine and beta-amyloid peptide 1-42. Free Radic Res. 2002; 36(11): 1179-84.

79. Offen D, et al. Use of thiols in treatment of PD. Exp Neurol. 1996; 141(1): 32-9.

80. Pocernich CB, et al. Glutathione elevation and its protective role in acrolein-induced protein damage in synaptosomal membranes: Relevance to brain lipid peroxidation in neurodegenerative disease. Neurochem Int. 2001; 39(2): 141-9.

81. Pearce RK, Owen A, Daniel S, Jenner P, Marsden CD. Alterations in the distribution of glutathione in the substantia nigra in Parkinson’s disease. J Neural Transm. 1997; 104(6-7): 661-77.

82. Shen XM, et al. Neurobehavioral effects of NAC conjugates of dopamine: possible relevance for Parkinson’s disease. Chem Res Toxicol. 1996; 9(7): 1117-26.

83. Li H, Shen XM, Dryhurst G. Brain mitochondria catalyze the oxidation of 7-(2-aminoethyl)-3, 4-dihydro-5-hydroxy-2H-1,4-benzothiazine-3-carboxylic acid (DHBT-1) to intermediates that irreversibly inhibit complex I and scavenge glutathione: potential relevance to the pathogenesis of Parkinson’s disease. J Neurochem. 1998; 71(5): 2049-62.

84. Araragi S, Sato M, et al. Mercuric chloride induces apoptosis via a mitochondrial-dependent pathway in human leukemia cells. Toxicology. 2003; 184(1): 1-9.

85. Campbell N, Godfrey M. Confirmation of mercury retention and toxicity using DMPS provocation. J of Advancement in Medicine. 1994; 7(1).

86. Zander D, et al. Mercury mobilization by DMPS in subjects with and without amalgams. Zentralbl Hyg Umweltmed. 1992; 192(5): 447-54.

87. Stejskal VDM, et al. MELISA: Tool for the study of metal allergy. Toxicology In Vitro. 1994; 8(5): 991-1000.

88. Lutz E, et al. Concentrations of mercury in brain and kidney of fetuses and infants. J Trace Elem Med Biol. 1996; 10: 61-67.

89. Drasch G, et al. Mercury burden of human fetal and infant tissues. Eur J Pediatr. 1994; 153: 607-610.

90. Thompson CM, Markesbery WR, et al. Regional brain trace-element studies in Alzheimer’s disease. Neurotoxicology. 1988; 9(1): 1-7.

91. Hock, et al. Increased blood mercury levels in Alzheimer’s patients. Neural. Transm. 1998, 105: 59-68.

92. Cornett, et al. Imbalances of trace elements related to oxidative damage in Alzheimer’s diseased brain. Neurotoxicolgy. 1998; 19: 339-345.

93. Vance DE, Ehmann WD, Markesbery WR. A search for longitudinal variations in trace element levels in nails of Alzheimer’s disease patients. Biol Trace Elem Res. 1990; 26-27: 461-70.

94. Ritchie KA, et al. Psychomotor testing of dentists with chronic low level mercur exposure. J Dent Res. 1995; 74: 420.

95. Gonzalez-Ramirez D, et al. Urinary mercury, porphyrins, and neurobehavioral changes of dental workers in Monterrey. J Pharmocology and Experimental Therapeutics. 1995; 272(1): 264-274.

96. Echeverria D, et al. Behavioral effects of low level exposure to Hg vapor among dentists. Neurotoxicology & Teratology. 1995; 17(2): 161-168.

97. Foo SC, et al. Neurobehavioral effects in occupational chemical exposure. Environ Res. 1993; 60(2): 267-273.

98. Mantyla DG, et al. Mercury toxicity in the dental office: A neglected problem. JADA. 1976; 92: 1189-1194.

99. Symington D. Mercury poisoning in dentists. J Soc Occup Med. 1980; 30: 37-39.

100. Koyun M, Akman S, Güven AG. Mercury intoxication resulting from school barometers in three unrelated adolescents. Eur J Pediatr. 2004;163(3): 131-4.

101. Zampollo A, et al. Subclinical inorganic mercury neuropathy: Neurophysiological investigations in 17 occupationally exposed subjects. Italian Journal of Neurological Sciences. 1987; 8(3).

102. Veltman JC, et al. Alterations of heme, cytochrome P-450, and steroid metabolism by mercury in rat adrenal gland. Arch Biochem Biophys. 1986; 248(2): 467-78.

103. Riedl AG, et al. P450 and hemeoxygenase enzymes in the basal ganglia and their roles in Parkinson’s disease. Adv Neurol. 1999; 80: 271-86.

104. Zamm AV. Dental mercury: A factor that aggravates and induces xenobiotic intolerance. J. Orthmol. Med. 1991; 6(2): 67-77.

105. Berglund F. Case Reports Spanning 150 Years on the Adverse Effects of Dental Amalgam. Orlando, FL: Bio-Probe, Inc.; 1995.

106. Tuthill JY. Mercurial neurosis resulting from amalgam fillings. The Brooklyn Medical Journal. 1988; 12(12): 725-742.

107. Redhe O, Pleva J. Recovery from ALS and from asthma after removal of dental amalgam fillings. Int J Risk & Safety in Med. 1994; 4: 229-236.

108. Adams CR, Ziegler DK, Lin JT. Mercury intoxication simulating ALS. JAMA. 1983; 250(5): 642-5.

109. Seidler A, et al. Possible environmental factors for Parkinson’s disease. Neurology. 1996; 46(5): 1275-1284.

110. Vroom FO, Greer M. Mercury vapor intoxication. 1972; 95: 305-318.

111. Ohlson, et al. Parkinson’s disease and occupational exposure to mercury. Scand J. of Work Environment Health. 1981; 7(4): 252-256.

112. Golota LG, Therapeutic properties of unitihiol. Farm. Zh. 1980; 1: 18-22.

113. Nylander M, et al. Mercury accumulation in tissues from dental staff and controls. Swed. Dent. J, 1989; 13: 235-243.

114. Nylander M, et al. Mercury and selenium concentrations and their interrelations in organs from dental staff and the general population. Br J Ind Med. 1991; 48(11): 729-34.

115. Siblerud RL, et al. Evidence that mercury from silver fillings may be an etiological factor in multiple sclerosis. Sci Total Environ. 1994; 142(3): 191-205.

116. Siblerud RL, Kienholz E. Evidence that mercury from dental amalgam may cause hearing loss in multiple sclerosis patients. J. Orthomol. Med. 1997; 12(4): 240-4.

117. Siblerud RL. A comparison of mental health of multiple sclerosis patients with silver dental fillings and those with fillings removed. Psychol Rep. 1992; 70(3.2); 1139-51.

118. Facemire CF, et al. Reproductive impairment in the Florida panther. Environ Health Perspect. 1995; 103(4): 79-86.

119. Yang JM, et al. The distribution of HgCl2 in rat body and its effect on fetus. Environ Sci. 1996; 9(4): 437-42.

120. Rao MV, Sharma PS. Protective effect of vitamin E against mercuric chloride reproductive toxicity in male mice. Reprod Toxicol. 2001; 15(6): 705-12.

121. Monsees TK, Franz M, Gebhardt S, Winterstein U, Schill WB, Hayatpour J. Sertoli cells as a target for reproductive hazards. Andrologia. 2000; 32(4-5): 239-46.

122. Maretta M, et al. Effect of mercury on the epithelium of the fowl testis. Vet Hung. 1995; 43(1): 153-6.

123. Orisakwe OE, Afonne OJ. Low-dose mercury induces testicular damage in mice that is protected against by zinc. Eur J Obstet Gynecol Reprod Biol. 2001; 95(1): 92-6.

124. Colborn T, ed. Chemically Induced Alterations in Functional Development. Princeton Scientific Press; 1992.

125. Giwercman A, Carlsen E, Keiding N, Skakkabaek NE. Evidence for increasing incidence of abnormalities of the human testis: A review. Environ Health Perspect. 1993; 101(2): 65-71.

126. Siblerud RL, et al. Psychometric evidence that mercury from dental fillings may be a factor in depression, anger, and anxiety. Psychol Rep. 1994; 74(1).

127. Henningsson M, et al. Defensive characteristics in individuals with amalgam illness. Acta Odont Scand. 1996; 54(3): 176-181.

128. Liang YX, et al. Psychological effects of low exposure to mercury vapor. Environmental Med Research. 1993; 60(2): 320-327.

129. Kampe T, et al. Personality traits of adolescents with intact and repaired dentitions. Acta Odont Scand. 1986; 44: 95.

130. Kishi R, et al. Residual neurobehavioral effects of chronic exposure to mercury vapor. Occupat. Envir. Med. 1994; 51: 35-41.

131. Sikora A, et al. Evaluation of mental functions in workers exposed to metallic mercury. Med Pr. 1992; 43(2): 109-21.

132. Roeleveld N, et al. Mental retardation and parental occupation. Br J Ind Med. 1993; 50(10): 945-954.

133. Quig D, Cysteine metabolism and metal toxicity. Altern Med Rev. 1998; 3(4): 262-270.

134. de Ceaurriz J, et al. Role of gamma-glutamyltraspeptidase (GGC) and extracellular glutathione in dissipation of inorganic mercury. J Appl Toxicol. 1994; 14(3): 201.

135. Berndt WO, et al. Renal glutathione and mercury uptake. Fundam Appl Toxicol. 1985; 5(5): 832-9.

136. Zalups RK, Barfuss DW. Accumulation and handling of inorganic mercury in the kidney after co-administration with glutathione. J Toxicol Environ Health. 1995; 44(4): 385-99.

137. Clarkson TW, et al. Billiary secretion of glutathione-metal complexes. Fundam Appl Toxicol. 1985; 5(5): 816-31.

138. Aschner M, et al. Metallothionein induction in fetal rat brain by in utero exposure to elemental mercury vapor. Brain Res. 1997; 8(1): 222-32.

139. Aschner M, Rising L, Mullaney KJ. Differential sensitivity of neonatal rat astrocyte cultures to mercuric chloride (MC) and methylmercury (MeHg): Studies on K+ and amino acid transport and metallothionein (MT) induction. Neurotoxicology. 1996; 17(1): 107-16.

140. O’Halloran TV. Transition metals in control of gene expression. Science. 1993; 261(5122): 715-25.

141. Matts RL, Schatz JR, Hurst R, Kagen R. Toxic heavy metal ions inhibit reduction of disulfide bonds. J Biol Chem. 1991; 266(19): 12695-702.

142. Boot JH. Effects of SH-blocking compounds on the energy metabolism in isolated rat hepatocytes. Cell Struct Funct. 1995; 20(3): 233-8.

143. Baauweegers HG, Troost D. Localization of metallothionein in the mammilian central nervous system. Biol Signals. 1994; 3: 181-7.

144. Ronnback L, et al. Chronic encephalopaties induced by low doses of mercury or lead. Br J Ind Med. 1992; 49: 233-240.

145. Langauer-Lewowicka H. Changes in the nervous system due to occupational metallic mercury poisoning. Neurol Neurochir Pol. 1997; 31(5): 905-13.

146. Langauer-Lewowicka H. Chronic toxic encephalopathies. Med Pr. 1982; 33(1-3): 113-7.

147. Tirado V, Garcia MA, et al. Pneuropsychological disorders after occupational exposure to mercury vapors in El Bagre (Antioquia, Colombia). Rev Neurol. 2000; 31(8): 712-6.

148. Powell TJ. Chronic neurobehavioural effects of mercury poisoning on a group of Zulu chemical workers. Brain Inj. 2000; 14(9): 797-814.

149. Haut MW, Morrow LA, et al. Neurobehavioral effects of acute exposure to inorganic mercury vapor. Appl Neuropsychol. 1999; 6(4): 193-200.

150. Kobal Grum D, Kobal AB. Personality traits in miners with past occupational elemental mercury exposure. Environ Health Perspect. 2006; 114(2): 290-6.

151. Ono B, et al. Reduced tyrosine uptake in strains sensitive to inorganic mercury. Genet. 1987; 11(5): 399.

152. Singh I, Pahan K, Khan M. Cytokine-mediated induction of ceramide production is redox-sensitive. Implications to pro-inflammatory cytokine-mediated apoptosis in demyelinating diseases. J Biol Chem. 1998; 273(32): 20354-62.

153. Pahan K, Raymond JR, Singh I. Inhibition of phosphatidylinositol 3-kinase induces nitric-oxide synthase in lipopolysaccharide- or cytokine-stimulated C6 glial cells. J Biol Chem. 1999; 274: 7528-7536.

154. Xu J, Yeh CH, et al. Involvement of de novo ceramide biosynthesis in tumor necrosis factor-alpha/cycloheximide-induced cerebral endothelial cell death. J Biol Chem. 1998; 273(26): 16521-6.

155. Dbaibo GS, El-Assaad W, et al. Ceramide generation by two distinct pathways in tumor necrosis factor alpha-induced cell death. FEBS Lett. 2001; 503(1): 7-12.

156. Liu B, Hannun YA, et al. Glutathione regulation of neutral sphingomyelinase in tumor necrosis factor-alpha-induced cell death. J Biol Chem. 1998; 273(18): 11313-20.

157. Noda M, Wataha JC, et al. Sublethal, 2-week exposures of dental material components alter TNF-alpha secretion of THP-1 monocytes. Dent Mater. 2003; 19(2): 101-5.

158. Kim SH, Johnson VJ, Sharma RP. Mercury inhibits nitric oxide production but activates pro-inflammatory cytokine expression in murine macrophage: Differential modulation of NF-kappaB and p38 MAPK signaling pathways. Nitric Oxide. 2002; 7(1): 67-74.

159. Dastych J, Metcalfe DD, et al. Murine mast cells exposed to mercuric chloride release granule-associated N-acetyl-beta-D-hexosaminidase and secrete IL-4 and TNF-alpha. J Allergy Clin Immunol. 1999; 103(6): 1108-14.

160. Tortarolo M, Veglianese P, et al. Persistent activation of p38 mitogen-activated protein kinase in a mouse model of familial amyotrophic lateral sclerosis correlates with disease progression. Mol Cell Neurosci. 2003; 23(2): 180-92.

161. Queiroz MLS, et al. Immunoglobulin levels in workers exposed to inorganic mercury. Pharmacol Toxicol. 1994; 74: 72-75.

162. Siblerud RL, et al. Evidence that mercury from dental fillings may be an etiological factor in smoking. Toxicol Lett. 1993; 68(3): 307.

163. Carpenter DO. Effects of metals on the nervous system of humans and animals. Int J Occup Med Environ Health. 2001; 14(3): 209-18.

164. Gorell JM, et al. Occupational exposure to mercury, manganese, copper, lead, and the risk of Parkinson’s disease. Neurotoxicology. 1999; 20(2-3): 239-47.

165. Gorell JM, et al. Occupational exposures to metals as risk factors for Parkinson’s disease. Neurology. 1997; 48(3): 650-8.

166. Discalzi G, Meliga F, et al. Occupational Mn parkinsonism: Magnetic resonance imaging and clinical patterns following CaNa2-EDTA chelation. Neurotoxicology. 2000; 21(5): 863-6.

167. Wood M. Mechanisms for the Neurotoxicity of Mercury, in Organotransitional Metal Chemistry. New York: Plenum Publishing Corp; 1987.

168. Sharma RP, et al. Metals and neurotoxic effects. J of Comp Pathology. 1981; 91.

169. Casdorph HR. Toxic Metal Syndrome. Avery Publishing Group; 1995.

170. Choi B, et al. Abnormal neuronal migration of human fetal brain. Journal of Neurophalogy. 1978; 37: 719-733.

171. Larkfors L, et al. Methyl mercury induced alterations in the nerve growth factor level in the developing brain. Res Dev Res. 1991; 62(2): 287.

172. Belletti S, Gatti R. Time course assessment of methylmercury effects on C6 glioma cells: submicromolar concentrations induce oxidative DNA damage and apoptosis. J Neurosci Res. 2002; 70(5): 703-11.

173. Wenstrup, et al. Trace element imbalances in the brains of Alzheimer’s patients. Research. 1990; 533: 125-131.

174. Lorscheider FL, Haley B, et al. Mercury vapor inhibits tubulin binding. FASEB J. 1995; 9(4): A-3485.

175. de Saint-Georges, et al. Inhibition by mercuric chloride of the in vitro polymerization of microtubules. CR Seances Soc Biol Fil. 1984; 178(5): 562-6.

176. Lorscheider FL, et al. Inorganic mercury and the CNS: Genetic linkage of mercury and antibiotic resistance. Toxicology. 1995; 97(1): 19-22.

177. Roberts MC. Antibiotic resistance in oral/respiratory bacteria. Crit Rev Oral Biol Med. 1998; 9 (4): 522.

178. Basun H, et al. Metals in plasma and cerebrospinal fluid in normal aging and Alzheimer’s disease. J Neural Transm Park Dis Dement Sect. 1991; 3(4): 231-58.

179. Ngim CH, et al. Epidemiologic study on the association between body burden mercury level and idiopathic Parkinson’s disease. Neuroepidemiology. 1989; 8(3): 128-41.

180. Monnet-Tschudi F, et al. Comparison of the developmental effects of 2 mercury compounds on glial cells and neurons in the rat telencephalon. Brain Res. 1996; 741: 52-59.

181. Chang LW, Hartmann HA. Quantitative cytochemical studies of RNA in experimental mercury poisoning. Acta Neruopathol(Berlin). 1973; 23(1): 77-83.

182. Sorensen FW, Larsen JO, Eide R, Schionning JD. Neuron loss in cerebellar cortex of rats exposed to mercury vapor: a stereological study. Acta Neuropathol (Berl). 2000; 100(1): 95-100.

183. Niederhofer H. Ginkgo biloba treating patients with attention-deficit disorder. Phytother Res. 2009.

184. Ingalls TH. Clustering of multiple sclerosis in Galion, Ohio, 1982-1985. Amer J Forensic Med Pathol. 1989; 10: 213-5.

185. Urban P, et al. Neurological examination on 3 groups of workers exposed to mercury vapor. Eur J Neurology. 1999; 6(5): 571-7.

186. Polakowska B. Neurological assessment of health status in dentists. Med Pr. 1994; 45(3): 221-5.

187. Ekenvall L, et al. Sensory perception in the hands of dentists. J Work Environ Health. 1990; 16(5): 334-9.

188. Kraub P, Deyhle M, Maier KH, Roller HD. Field study on the mercury content of saliva. Heavy Metal Bull. 1996; 3(1).

189. Warren T. Beating Alzheimer’s. Avery Publishing Group; 1991.

190. Berlin M. Is amalgam in dental fillings hazardous to health? Lakartidningen. 1992; 89(37): 2918-23.

191. Berlin M, et al. Prenatal exposure to mercury vapor: effects on brain development. The Toxicologist. 1992; 12(1): 7(A245).

192. Ziff MF. Documented clinical side effects to dental amalgams. Adv Dent Res. 1992; 1(6): 131-134.

193. Ziff S. Dentistry without Mercury. 8th ed. Orland, FL: Bio-Probe, Inc.; 1996.

194. Siblerud, RL. Health effects after dental amalgam removal. J. Orthomol. Med. 1990; 5: 95-106.

195. Zamm AV. Removal of dental mercury: often an effective treatment for the very sensitive patient. J Orthomol. Med. 1990; 5: 138-142.

196. Cutright et al. Systemic mercury levels caused by inhaling mist during high-speed amalgam grinding. J Oral Med. 1973; 28(4): 100-104.

197. Nimmo A, et al. Inhalation during removal of amalgam restorations. J Prosthet Dent. 1990; 63(2): 228-33.

198. Stonehouse CA, Newman AP. Mercury vapour release from a dental aspirator. Br Dent J. 2001; 190(10): 558-60.

199. Taskinen H, Kinnunen E, Riihimaki V. A possible case of mercury-related toxicity resulting from the grinding of old amalgam restorations. Scand J Work Environ Health. 1989; 15 (4): 302-4.

200. Shenker BJ, et al. Immunotoxic effects of mercuric compounds on human lymphocytes and monocytes: Alterations in cell viability. Immunopharmacologicol Immunotoxical. 1992; 14(3): 555-77.

201. Miller MA, et al. Mercuric chloride induces apoptosis in human T lymphocytes. Toxicol Appl Pharmacol. 1998; 153(2): 250-7.

202. Rossi AD, Viviani B, Vahter M. Inorganic mercury modifies Ca2+ signals, triggers apoptosis, and potentiates NMDA toxicity in cerebral granule neurons. Cell Death and Differentiation. 1997; 4(4): 317-24.

203. Thomas D, Rojko JL, Lucas AD. Mercuric chloride-induced apoptosis is dependent on protein synthesis. Toxicol Lett. 1999; 105(3): 183-95.

204. Shenker BJ, et al. Immune suppression of human T-cell activation. Immunopharmacologicol Immunotoxical. 1992; 14(3): 555-77.

205. Zamm AF. Removal of dental mercury: Often an effective treatment for very sensitive patients. J Orthomolecular Med. 1990; 5(53): 138-142.

206. Cutler E. Winning the War Against Asthma & Allergies. Delmar Learning; 1997.

207. Davis M, ed. Defense Against Mystery Syndromes. Chek Printing Co; 1994.

208. Cutler A. Amalgam Illness Diagnosis and Treatment.

209. Berglund F, et al. Improved health after removal of dental fillings. Swedish Assoc. Of Dental Mercury Patients. 1998.

210. Lindforss H, Marqvardsen O, Olsson S, Henningsson M. Effects on health after removal of amalgam fillings. Tandläkartidn. 1994; 86(4): 205-211.

211. Olsson G, Lindh U. Veränderung des allgemeinen gesundheitszustand nach amalgamentfernung. GZM. 1997; 2(1): 22-28.

212. Strömberg, R, Langworth, S. Does health improve after removal of amalgam? Tandläkartidn. 1998; 90(9): 23-29.

213. Klock B, Blomgren J, Ripa U, Andrup B. Effect of amalgam removal in patients who suspect amalgam poisoning. Tandläkartidningen. 1989; 81: 1297-1302.

214. Dooley MA, et al. Occupational risk factors for the development of systemic lupus erythematosus. J Rheumatol. 2004; 31(10): 1928-33.

215. Bigazzi PE. Autoimmunity and heavy metals. Lupus. 1994; 3: 449-453.

216. Pollard KM, Pearson Dl, Hultman P. Lupus-prone mice as model to study xenobiotic-induced autoimmunity. Environ Health Perspect. 1999; 107(5): 729-735.

217. Nielsen JB, Hultman P. Experimental studies on genetically determined susceptibility to mercury-induced autoimmune response. Ren Fail. 1999; 21(3-4): 343-8.

218. Hultman P, Enestrom S. Mercury induced antinuclear antibodies in mice. Clinical and Exper Immunology. 1988; 71(2): 269-274.

219. Robbins SM, Quintrell NA, Bishop JM. Mercuric chloride activates the Src-family protein tyrosine kinase, Hck in myelomonocytic cells. Eur J Biochem. 2000; 267(24): 7201-8.

220. Via CS, Nguyen P, Silbergeld EK, et al. Low-dose exposure to inorganic mercury accelerates disease and mortality in acquired murine lupus. Environ Health Perspect. 2003, 111(10): 1273-7.

221. Silbergeld EK, Nyland JF. Mercury and autoimmunity: implications for occupational and environmental health. Toxicol App Pharmacol. 2005; 207 (2): 282-92.

222. Schoeny R. Use of genetic toxicology data in U.S. EPA risk assessment: The mercury study. Environ Health Perspect. 1996; 104(3): 663-73.

223. Iyer K, et al. Mercury poisoning in a dentist. Arch Neurol. 1976; 33: 788-790.

224. Finkelstein Y. The enigma of parkinsonism in chronic borderline mercury intoxication, resolved by challenge with penicillamine. Neurotoxicology. 1996; 17(1): 291-5.

225. Hryhorczuk E, et al. Treatment of mercury intoxication in a dentist with penicilamine. J Toxicol Clin Toxicol. 1982; 19(4): 401.

226. Ngim CH, et al. Chronic neurobehavioral effects of elemental mercury in dentists. British Journal of Industrial Medicine. 1992; 49(11): 782-790.

227. Rybicki BA, et al. Parkinson’s disease mortality and the industrial use of heavy metals in Michigan. Mov Disord. 1993; 8(1): 87-92.

228. Yamanaga H. Quantitative analysis of tremor in Minamata disease. Tokhoku J Exp Med. 1983; 141(1): 13-22.

229. Omura Y, et al. Role of mercury in resistant infections and recovery after Hg detox with cilantro. Acupuncture & Electro-Therapeutics Research. 1995; 20(3): 195-229.

230. Omura, Yoshiaki. Abnormal deposits of Al, Pb, and Hg in the brain, particularly in the hippocampus, as one of the main causes of decreased cerebral cetylcholine, electromagnetic field hypersensitivity, pre-Alzheimer’s disease, and autism in children; Acupuncture & Electro-Therapeutics Research. 2000; 25(3/4): 230.

231. Mortada WL, Sobh MA, El-Defrawy MM, Farahat SE. Mercury in dental restoration: Is there a risk of nephrotoxicity? J Nephrol. 2002; 15(2): 171-6.

232. Zabinski Z, Dabrowski Z, Moszczynski P, Rutowski J. The activity of erythrocyte enzymes and basic indices of peripheral blood erythrocytes from workers chronically exposed to mercury vapors. Toxicol Ind Health. 2000; 16(2): 58-64.

233. Rice DC. Evidence of delayed neurotoxicity produced by methyl mercury developmental exposure. Neurotoxicology. 1996; 17(3-4): 583-96.

234. Weiss B, Clarkson TW, Simon W. Silent latency periods in methylmercury poisoning and in neurodegenerative disease. Environ Health Perspect. 2002; 110(5): 851-4.

235. Smith I, et al. Pteridines and mono-amines: Relevance to neurological damage. Postgrad Med J. 1986; 62(724): 113-123.

236. Kay AD, et al. Cerebrospinal fluid biopterin is decreased in Alzheimer’s disease. Arch Neurol. 1986; 43(10): 996-9.

237. Yamiguchi T, et al. Effects of tyrosine administration on serum bipterin in patients with Parkinson’s disease and normal controls. Science. 1983; 219(4580): 75-77.

238. Nagatsu T, et al. Catecholoamine-related enzymes and the biopterin cofactor in Parkinson’s. Neurol. 1984; 40: 467-73.

239. Ely, JTA. Mercury induced Alzheimer’s disease: Accelerating incidence? Bull Environ Contam Toxicol. 2001; 67: 800-6.

240. Chang LW. The Neurotoxicology and pathology of organomercury, organolead, and organotin. J Toxicol Sci. 1990; 15(4): 125-51.

241. Chang LW. Latent effects of methyl mercury on the nervous system after prenatal exposure. Environ Res. 1977; 13(2): 171-85.

242. Danielsson BR, et al. Behavioral effects of prenatal metallic mercury inhalation exposure in rats. 1993; 15(6): 391-6.

243. Fredriksson, et al. Prenatal exposure to metallic mercury and methyl mercury produce interactive behavioral changes in adult rats. Neurotoxicol Teratol. 1996; 18(2): 129-34.

244. Friberg L, et al. Mercury in the brain and CNS in relation to amalgam fillings. Swedish Medical Journal. 1986; 83(7): 519-521.

245. Mikhailova LM, et al. Influence of occupational factors on disease of reproductive organs. Pediatriya Akusherstvoi Ginekologiya. 1971; 33(6): 56-58.

246. Elghany NA, Stopford W, Bunn WB, Fleming LE. Occupational exposure to inorganic mercury vapour and reproductive outcomes. Occup Med (Lond). 1997; 47(6): 333-6.

247. Perlingeiro RC, et al. Polymorphonuclear phagentosis in workers exposed to mercury vapor. Int J Immounopharmacology. 1994; 16(12): 1011-7.

248. Albers JW, et al. Neurological abnormalities associated with remote occupational elemental mercury exposure. Ann Neurol. 1988; 24(5): 651-9.

249. Soleo L, et al. Effects of low exposure to inorganic mercury on psychological performance. Br J Ind Med. 1990; 47(2): 105-9.

250. Smith PJ, et al. Effect of exposure to elemental mercury on short term memory. Br J Ind Med. 1983; 40(4): 413-9.

251. Hua MS, et al. Chronic elemental mercury intoxication. Brain Inj. 1996; 10(5): 377-84.

252. Gunther W, et al. Repeated neurobehavioral investigations in workers. Neurotoxicology. 1996; 17(3-4): 605-14.

253. Lai M, et al. Sensitivity of MS detections by MRI. Journal of Neurology, Neurosurgery, and Psychiatry. 1996; 60(3): 339-341.

254. Newland MC, et al. Behavioral consequences of in utero exposure to mercury vapor in squirrel monkeys. Toxicol App Pharmacol. 1996; 139: 374-386.

255. Newland MC, et al. Prolonged behavioral effects of in utero exposure to methyl mercury or lead. Toxicol Appl Pharmacol. 1994; 126(1): 6-15.

256. Warfvinge K, et al. Mercury distribution in neonatal cortical areas after exposure to mercury vapor. Environ Res. 1994; 67: 196-208.

257. Hisatome I, Kurata Y, et al. Block of sodium channels by divalent mercury: role of specific cysteinyl residues in the P-loop region. Biophys J. 2000; 79(3): 1336-45.

258. Bhattacharya S, Sen S, et al. Specific binding of inorganic mercury to Na(+)-K(+)-ATPase in rat liver plasma membrane and signal transduction. Biometals. 1997; 10(3): 157-62.

259. Anner BM, Moosmayer M, Imesch E. Mercury blocks Na-K-ATPase by a ligand-dependent and reversible mechanism. Am J Physiol. 1992; 262(5.2): F830-6.

260. Anner BM, Moosmayer M. Mercury inhibits Na-K-ATPase primarily at the cytoplasmic side. Am J Physiol. 1992; 262(5.2): F84308.

261. Wagner, Waldegger S, et al. Heavy metals inhibit Pi-induced currents through human brush-border NaPi-3 cotransporter in Xenopus oocytes. Am J Physiol. 1996; 271(4.2): F926-30.

262. Rajanna B, Hobson M, Harris L, Ware L, Chetty CS. Effects of cadmium and mercury on Na(+)-K(+) ATPase and uptake of 3H-dopamine in rat brain synaptosomes. Arch Int Physiol Biochem. 1990; 98(5): 291-6.

263. Hobson M, Rajanna B. Influence of mercury on uptake of dopamine and norepinephrine. Toxicol Letters. 1985; 27(2-3): 7-14.

264. McKay SJ, Reynolds JN, Racz WJ. Effects of mercury compounds on the spontaneous and potassium-evoked release of [3H] dopamine from mouse striatial slices. Can J Physiol Pharmacol. 1986; 64(12): 1507-14.

265. Scheuhammer AM; Cherian MG. Effects of heavy metal cations, sulfhydryl reagents and other chemical agents on striatal D2 dopamine receptors. Biochem Pharmacol. 1985; 34(19): 3405-13.

266. Hoyt KR, et al. Mechanisms of dopamine-induced cell death and differences from glutamate induced cell death. Exp Neurol. 1997; 143(2): 269-81.

267. Echeverria D, et al. Neurobehavioral effects from exposure to dental amalgam: new distinctions between recent exposure and Hg body burden. FASEB J. 1998; 12(11): 971-980.

268. Woods JS, Heyer NJ, Rohlman DS, et al. Chronic low-level mercury exposure, BDNF polymorphism, and associations with cognitive and motor function. Neurotoxicol Teratol. 2005; 27(6): 781-96.

269. Echeverria D, Woods JS, et al. The association between a genetic polymorphism of coproporphyrinogen oxidase, dental mercury exposure and neurobehavioral response in humans. Neurotoxicol Teratol. 2006; 28(1): 39-48.

270. Huggins HA, Levy TE. Cerebrospinal fluid protein changes in MS after Dental amalgam removal. Alternative Med Rev. 1998; 3(4): 295-300.

271. Siblerud, Robert L., et al. Psychometric evidence that dental amalgam mercury may be an etiological factor in manic depression. Journal of Orthomolecular Medicine. 1998; 13(1); 31-40.

272. Lieb J, Hershman D. Isaac Newton: Mercury poisoning or manic depression? Lancet. 1983; 2(8365-66): 1479-80.

273. Bennett, Plum. Cecil Textbook of Medicine. 20th ed. Philadelphia: W.B. Saunders and Co.; 1996: 69.

274. Sunderman FW. Perils of mercury. Ann Clin Lab Sci. 1988; 18(2): 89-101.

275. Bucio L, et al. Uptake, cellular distribution and DNA damage produced by mercuric chloride in a human fetal hepatic cell line. Mutat Res. 1999; 423(1-2): 65-72.

276. Ho PI, Ortiz D, Rogers E, Shea TB. Multiple aspects of homocysteine neurotoxicity: glutamate excitotoxicity, kinase hyperactivation and DNA damage. J Neurosci Res. 2002; 70(5): 694-702.

277. Snyder RD, Lachmann PJ. Thiol involvement in the inhibition of DNA repair by metals in mammalian cells. Source Mol Toxicol. 1989; 2(2): 117-28.

278. Verschaeve L, et al. Comparative in vitro cytogenetic studies in mercury-exposed human lymphocytes. Muta Res. 1985; 157(2-3): 221-6.

279. Verschaeve L. Genetic damage induced by low level mercury exposure. Environ Res. 1976; 12: 306-10.

280. Messer RL, Lockwood PE. Mercury (II) alters mitochondrial activity of monocytes at sublethal doses via oxidative stress mechanisms. J Biomed Mater Res B Appl Biomater. 2005; 75(2): 257-63.

281. Linnane AW, et al. Mitochondrial DNA mutations as an important contributor to aging and degenerative diseases. Lancet. 1989; 1(8639): 642-5.

282. Cho DH, et al. Mitochondrial dynamics in cell death and neurodegeneration. Cell Mol Life Sci. 2010.

283. Wei YH, et al. Mitochondrial theory of aging: roles of mtDNA mutation and oxidative stress in human aging. Zhonghua Yi Xue Za Zhi (Taipai). 2001; 64(5): 259-70.

284. Conley KE, et al. Mitochondrial function, fibre types, and aging. Exp Physiol. 2007; 92(2): 333-9.

285. Bugger H, et al. Mitochondria in the diabetic heart. Cardiovascular Research. 2010.

286. Lesnefsky EJ, et al. Mitochondrial dysfunction in cardiac disease: ischemia-reperfusin, aging, and heart failure. J Mol Cell Cardiol. 2001, 33(6): 1065-69.

287. Maruszak A, et al. Mitochondrial dysfunction and Alzheimer’s disease. Prog Neurophyschopharacol Biol Pyschiatry. 2010.

288. Nunome K, et al. PPQ prevents oxidative stress- induced neuronal death through changes in oxidative status of DJ-1. Biol Pharm Bull. 2008; 31(7): 1321-6.

289. Singh KK. Mitochondria damage checkpoint, aging, and cancer. Ann NY Acad Sci. 2006; 1067: 182-90.

290. Hock C, et al. Increased blood mercury levels in patients with Alzheimer’s disease. J. Neural Transm. 1998; 105(1): 59-68.

291. Chang LW. Neurotoxic effects of mercury. Environ. Res. 1977; 14(3): 329-73.

292. Aposhian HV. Mobilization of mercury and arsenic in humans by sodium 2, 3-dimercapto-1-propane sulfonate (DMPS). Environ Health Perspect. 1998; 106(4): 1017-25.

293. Soderstrom S, Fredriksson A, Dencker L, Ebendal T. The effect of mercury vapor on cholinergic neurons in the fetal brain. Brain Research: Developmental Brain Res. 1995; 85: 96-108.

294. Abdulla EM, et al. Comparison of neurite outgrowth with neurofilament protein levels in neuroblastoma cells following mercuric oxide exposure. Clin Exp Pharmocol Physiol. 1995; 22(5): 362-3.

295. Leong CC, Syed NI, Lorscheider FL. Retrograde degeneration of neurite membrane structural integrity of nerve growth cones following in vitro exposure to mercury. Neuroreport. 2001; 12(4): 733-7.

296. Stejskal VDM, et al. Mercury-specific Lymphocytes: an indication of mercury allergy in man. J. of Clinical Immunology. 1996; 16(1): 31-40.

297. Zinecker S. Amalgam: Quecksilberdamfe bis ins gehirn. Der Kassenarzt. 1992; 32(4): 23.

298. Malt UF, et al. Physical and mental problems attributed to dental amalgam fillings. Psychosomatic Medicine. 1997; 59: 32-41.

299. Engel P. Beobachtungen uber die gesundheit vor und nach amalgamentfernug. Separatdruck aus Schweiz Monatsschr Zahnm. 1998; 108(8).

300. Bangsi D, Ghadirian P, et al. Dental amalgam and multiple sclerosis. International J of Epidemiology. 1998; 27(4): 667-71.

301. Mauch E, et al. Umweltgifte und multiple sklerose. Der Allgremeinarzt. 1996; 20: 2226-2220.

302. McGrother CW, Dugmore C, Phillips MJ, et al. Multiple sclerosis, dental caries and fillings: A case-control study. Br Dent J. 1999; 187(5): 261-4.

303. Baasch E. Is multiple sclerosis a mercury allergy? Schweiz arch Neurol Neurochir Psichiatr. 1966; 98: 1-19.

304. Clausen J. Mercury and MS. Acta Neurol Scand. 1993; 87: 461.

305. Le Quesne P. Metal-induced diseases of the nervous system. Br J Hosp Med. 1982; 28: 534.

306. Danscher G, et al. Localization of mercury in the CNS. Environ Res. 1986; 41: 29-43.

307. Danscher G, Horsted-Bindslev P, Rungby J. Traces of mercury in organs from primates with amalgam fillings. Exp Mol Pathol. 1990; 52(3): 291-9.

308. Pamphlett R, Coote P. Entry of low doses of mercury vapor into the nervous system. Neurotoxicology. 1998; 19(1): 39-47.

309. Pamphlett, et al. Oxidative damage to nucleic acids in motor neurons containing Hg. J Neurol Sci. 1998; 159(2): 121-6.

310. Pamphlett R, Waley P. Motor neuron uptake of low dose inorganic mercury. J. Neurological Sciences. 1996; 135: 63-67.

311. Schionning JD, Danscher G. Autometallographic inorganic mercury correlates with degenerative changes in dorsal root ganglia of rats intoxicated with organic mercury. APMIS. 1999; 107(3): 303-10.

312. Arvidson B, Arvidsson J, Johansson K. Mercury deposits in neurons of the trigeminal ganglia after insertion of dental amalgam in rats. Biometals. 1994; 7(3): 261-263.

313. Arvidson B. Inorganic mercury is transported from muscular nerve terminasl to spinal and brainstem motor neurons. Muscle Nerve. 1992; 15: 1089-94.

314. Arvidson B, Arvidsson J. Retrograde axonal transport of mercury in primary sensory neurons innervating the tooth pulp in the rat. Neurosci Lett. 1990; 115(1): 29-32.

315. Candura SM, et al. Effects of mercuric chloride and methyl mercury on cholinergic neuromusular transmission. Pharmacol Toxicol. 1997; 80(5): 218-24.

316. Castoldi AF, et al. Interaction of mercury compounds with muscarinic receptor subtypes in the rat brain. Neurotoxicology. 1996; 17(3-4): 735-41.

317. Freitas AJ, et al. Effects of Hg2+ and CH3Hg+ on Ca2+ fluxes in the rat brain. Brain Res. 1996; 738(2): 257-64.

318. Yallapragoda PR, et al. Inhibition of calcium transport by Hg salts in rat cerebellum and cerebral cortex. J Appl Toxicol. 1996; 164(4): 325-30.

319. Chavez E, et al. Mitochondrial calcium release by Hg+2. J Biol Chem. 1988; 263(8): 3582.

320. Szucs A, et al. Effects of inorganic mercury and methylmercury on the ionic currents of cultured rat hippocampal neurons. Cell Mol Neurobiol. 1997; 17(3): 273-8.

321. Busselberg D. Calcium channels as target sites of heavy metals. Toxicol Lett. 1995; 82-83: 255-61.

322. Rossi AD, et al. Modifications of Ca2+ signaling by inorganic mercury in PC12 cells. FASEB J. 1993; 7:1507-14.

323. Stejskal VDM, Danersund A, Lindvall A, et al. Metal-specific memory lymphocytes: biomarkers of sensitivity in man. Neuroendocrinology Letters. 1999; 20: 289-98.

324. Gerhard I. Amalgam from gynacological view. Der Frauenarzt. 1995; 36(6): 627-28.

325. Sterzl I, Prochazkova J, Stejskal VDM et al. Mercury and nickel allergy: risk factors in fatigue and autoimmunity. Neuroendocrinology Letters. 1999; 20: 221-228.

326. Prochazkova J, Sterzl I, Kucerova H, Bartova J, Stejskal VD; The beneficial effect of amalgam replacement on health in patients with autoimmunity. Neuroendocrinology Letters. 2004; 25(3): 211-8.

327. Kosuda LL, Greiner DL, Bigazzi PE. Effects of HgCl2 on the expression of autoimmune responses and disease in diabetes-prone (DP) BB rats. Autoimmunity. 1997; 26(3): 173-87.

328. Atchison WD. Effects of neurotoxicants on synaptic transmission. Neurotoxicol Teratol. 1998; 10(5): 393-416.

329. Sidransky H, Verney E. Influence of lead acetate and selected metal salts on tryptophan binding to rat hepatic nuclei. Toxicol Pathol. 1999; 27(4): 441-7.

330. Shukla GS, Chandra SV. Effect of interaction of Mn2+withZn2+, Hg2+, and Cd2+ on some neurochemicals in rats. Toxicol Lett. 1982; 10(2-3): 163-8.

331. Brouwer M, et al. Functional changes induced by heavy metal ions. Biochemistry. 1982; 21(20): 2529-38.

332. Benkelfat C, et al. Mood lowering effect of tryptophan depletion. Arch Gen Psychiatry. 1994; 51(9): 687-97.

333. Young SN, et al. Tryptophan depletion causes a rapid lowering of mood in normal males. Psychopharmacology. 1985; 87(2): 173-77.

334. Smith KA, et al. Relapse of depression after depletion of tryptophan. Lancet. 1997; 349(9056): 915-19.

335. Delgado PL, et al. Serotonin function, depletion of plasma tryptophan, and the mechanism of antidepressant action. Arch Gen Psychiatry. 1990; 47(5): 411-18.

336. Demitrack MA, Dale JK. Evidence for impaired activation of the hypothalamic-pituitary-adrenal axis in patients with chronic fatigue syndrome. J Clin Endocrinol Metabol. 1991; 73:1224-1234.

337. Turnbull AV, Rivier C. Regulation of the HPA axis by cytokines. Brain Behav Immun. 1995; 20: 253-75.

338. Ng TB, Liu WK. Toxic effect of heavy metals on cells isolated from the rat adrenal and testis. In Vitro Cell Dev Biol. 1990; 26(1): 24-8.

339. Baranski B. Effect of mercury on the sexual cycle and prenatal and postnatal development of progeny. Med Pr. 1981; 32(4): 271-6.

340. Hooper A. Mercury poisoning in dentistry. Wisconsin Medical J. 1980; 79.

341. Shapiro IM, Cornblath DR, Sumner AJ. Neurophysiological and neuropsychological function in mercury-exposed dentists. Lancet. 1982; 1: 1147-1150.

342. Uzzell BP and Oler J. Chronic low-level mercury exposure and neuropsychological functioning. J of Clin and Exper Neuropsych. 1986; 8: 581-93.

343. Ger. F, Letz R. Epidemiological case definitions of peripheral neuropathy. Neurotoxicology. 2000; 21(5): 761-8.

344. Letz R, Ger F, et al. Residual neurologic deficits 30 years after occupational exposure to elemental mercury. Neurotoxicology. 2000; 21(4): 459-74.

345. Chu CC, Wu TL, et al. Chronic inorganic mercury induced peripheral neuropathy. Acta Neurol Scand. 1998; 98(6): 461-5.

346. Stejskal J, Stejskal V. The role of metals in autoimmune diseases and the link to neuroendocrinology. Neuroendocrinology Letters. 1999; 20: 345-358.

347. Bernard S, Enayati A, Redwood L, Roger H, Binstock T. Autism: A novel form of mercury poisoning. Med Hypotheses. 2001; 56(4): 462-71.

348. Moreno-Fuenmayor H, Borjas L, Arrieta A, Valera V. Plasma excitatory amino acids in autism. Invest Clin. 1996; 37(2): 113-28.

349. Carlsson ML. Is infantile autsim a hypoglutamatergic disorder? J Neural Transm. 1998; 105(4-5): 525-35.

350. Rolf LH, Haarman FY, Grotemeyer KH, Kehrer H. Serotonin and amino acid content in platelets of autistic children. Psychiatr Scand. 1993; 87(5): 312-6.

351. Naruse H, Hayashi T, Takesada M, Yamazaki K. Metabolic changes in aromatic amino acids and monoamines in infantile autism and a new related treatment. No To Hattatsu. 1989; 21(2): 181-9.

352. Plaitakis A, Constantakakis E. Altered metabolism of excitatory amino acids, N-acetyl-aspartate and -acetyl-aspartyl-glutamate in amyotrophic lateral sclerosis. Brain Res Bull. 1993; 30(3-4): 381-6.

353. Rothstein JD, Martin LJ, Kuncl RW. Decreased glutamate transport by the brain and spinal cord in ALS. New Engl J Med. 1992; 326: 1464-8.

354. Leigh PN. Pathologic mechanisms in ALS and other motor neuron diseases. In: Calne DB, ed. Neurodegenerative Diseases. Philadelphia: W.B. Saunder Co; 1997: 473-88.

355. Froissard P, et al. Role of glutathione metabolism in the glutamate-induced programmed cell death of neuronal cells. Eur J Pharmacol. 1997; 236(1): 93-99.

356. Kim P, Choi BH. Selective inhibition of glutamate uptake by mercury in cultured mouse astrocytes. Yonsei Med J. 1995; 36(3): 299-305.

357. Brookes N. In vitro evidence for the role of glutatmate in the CNS toxicity of mercury. Toxicology. 1992; 76(3): 245-56.

358. Albrecht J, Matyja E. Glutamate: A potential mediator of inorganic mercury toxicity. Metab Brain Dis. 1996; 11: 175-84.

359. Tirosh O, Sen CK, Roy S, Packer L. Cellular and mitochondrial changes in glutamate-induced HT4 neuronal cell death. Neuroscience. 2000; 97(3): 531-41.

360. Barber T. Inorganic mercury intoxication similar to ALS. J of Occup Med. 1978; 20: 667-9.

361. Brown IA. Chronic mercurialism: A cause of the clinical syndrome of ALS. Arch Neurol Psychiatry. 1954; 72: 674-9.

362. Schwarz S, Husstedt I. ALS after accidental injection of mercury. J Neurol Neurosurg Psychiatry. 1996; 60: 698.

363. Felmus MT, Patten BM, Swanke L. Antecedent events in amyotrophic lateral sclerosis. Neurology. 1976; 26(2): 167-72.

364. Patten BM, Mallette LE. Motor neuron disease: retrospective study of associated abnormalities. Dis Nerv Syst. 1976; 37(6): 318-21.

365. Kantarjian A. A syndrome clinically resembling amyotrophic lateral sclerosis following chronic mercurialism. Neurology. 1961; 11: 639-644.

366. Munch G, Gerlach M, Sian J, Wong A, Riederer P. Advanced glycation end products in neurodegeneration: More than early markers of oxidative stress? Ann Neurol. 1998; 44(3.1): S85-8.

367. Sutton KG, McRory JE, Guthrie H, Snutch TP. P/Q-type calcium channels mediate the activity-dependent feedback of syntaxin-1A. Nature. 1999; 401(6755): 800-4.

368. Olanow CW, Arendash GW. Metals and free radicals in neurodegeneration. Curr Opin Neurol. 1994; 7(6): 548-58.

369. Troy CM, Shelanski ML. Down-regulation of copper/zinc superoxide dismutase causes apoptotic death in PC12 neuronal cells. Proc. National Acad Sci, USA. 1994; 91(14): 6384-7.

370. Rothstein JD, Dristol LA, Hosier B, Brown RH, Kunci RW. Chronic inhibition of superoxide dismutase produces apoptotic death of spinal neurons. Proc Nat Acad Sci, USA. 1994; 91(10): 4155-9.

371. Beal MF. Coenzyme Q10 administration and its potential for treatment of neurodegenerative diseases. Biofactors. 1999; 9(2-4): 262-6.

372. DiMauro S, Moses LG. CoQ10 use leads to dramatic improvements in patients with muscular disorder. Neurology. 2001.

373. Schultz C, et al. CoQ10 slows progression of Parkinson’s disease. Archives of Neurology. 2002.

374. Matthews RT, Yang L, Browne S, Baik M, Beal MF. Coenzyme Q10 administration increases brain mitochondrial concentrations and exerts neuroprotective effects. Proc Natl Acad Sci, USA. 1998; 95(15): 8892-7.

375. Schulz JB, Matthews RT, Henshaw DR, Beal MF. Neuroprotective strategies for treatment of lesions produced by mitochondrial toxins: Implications for neurodegenerative diseases. Neuroscience. 1996; 71(4): 1043-84.

376. Nagano S, Ogawa Y, Yanaghara T, Sakoda S. Benefit of a combined treatment with trientine and ascorbate in familial amyotrophic lateral sclerosis model mice. Neurosci Lett. 1999; 265(3): 159-62.

377. Gooch C, et al. Eleanor & Lou Gehrig MDA/ALS Center at Columbia-Presbyterian Center in New York. ALS Newsletter. 2001; 6(3).

378. Kidd PM. Neurodegeneration from mitochondrial insufficiency: nutrients, stem cells, growth factors, and prospects for brain rebuilding using integrative management. Altern Med Rev. 2005; 10(4): 268-293.

379. Schaumburg H, Spencer P. Toxic Neuropathies. Neurology. 1979; 29: 431.

380. Levine SP, Cavender GD, Langolf GD, Albers JW. Elemental mercury exposure: peripheral neurotoxicity. Br J Ind Med. 1982; 39(2): 136-9.

381. Miszta H, Dabrowski Z. Effect of mercury and combined effect of mercury on the activity of acetylcholinesterase of rat lymphocytes during in vitro incubation. Folia Haematol Int Mag Klin Morphol Blutforsch. 1989; 116(1): 151-5.

382. Bear D, Rosenbaum J, Norman R. Aggression in cat and human precipitated by a cholinesterase inhibitor. The Journal Psychosomatics. 1986; 27(7): 535-536.

383. Devinsky O, Kernan J, Bear D. Aggressive behavior following exposure to cholinesterase inhibitors. Journal of Neuropsychiatry. 1992; 4(2): 189-199.

384. Blumer W. Mercury toxicity and dental amalgam fillings. J Adv Med. 1998; 11(3): 219.

385. Olivieri G, Brack C, Muller-Spahn F, et al. Mercury induces cell cytotoxicity and oxidative stress and increases beta-amyloid secretion and tau phosphorylation in SHSY5Y neuroblastoma cells. J Neurochem. 2000; 74(1): 231-6.

386. Tabner BJ, Turnbull S, El-Agnaf OM, Allsop D. Formation of hydrogen peroxide and hydroxyl radicals from A(beta) and alpha-synuclein as a possible mechanism of cell death in Alzheimer’s disease and Parkinson’s disease. Free Radic Biol Med. 2002; 32(11): 1076-83.

387. Ho PI, Collins SC, et al; Homocysteine potentiates beta-amyloid neurotoxicity: Role of oxidative stress. J Neurochem. 2001; 78(2): 249-53.

388. van Benschoten. Acupoint energetics of mercury toxicity and amalgam removal with case studies. American Journal of Acupuncture. 1994; 22(3): 251-262.

389. Institute for Molecular Medicine.

390. Geier MR, Geier DA. Timerosal in childhood vaccines, neurodevelopmental disorders, and heart disease in the US. J of Amer Physicians and Surgeons. 2003; 8(1).

391. Landner L, Lindestrom L. Copper in Society and the Environment. 2nd ed. Swedish Environmental Research Group (MFG); 1999.

392. Salzer HM. Relative hypoglycemia as a cause of neuropsychiatric illness. J National Med Assoc. 1996; 58(1): 12-17.

393. Heninger GR, et al. Depressive symptoms, glucose tolerance, and insulin tolerance. J Nervous and Mental Dis. 1975; 161(6): 421-32.

394. Winokur A, et al. Insulin resistance in patients with major depression. Am J Psychiatry. 1988;145(3): 325-30.

395. Virkkunen M, Huttunen MO. Evidence for abnormal glucose tolerance among violent offenders. Neuropsychiobilogy. 1982; 8: 30-40.

396. Markku I, Virkkunen L. Aggression, suicidality, and serotonin. J Clinical Psy 1992; 53(10): 46-51.

397. Pranjic N, Sinanovic O, et al. Assessment of chronic neuropsychological effects of mercury vapour poisoning in chloral-alkali plant workers. Bosn J Basic Med Sci. 2002; 2(1-2): 29-34.

398. Linnoila M, et al. Low serotonin metabolite differentiates impulsive from non-impulsive violent behavior. Life Sciences. 1983; 33(26): 2609-2614.

399. Lopez-Ibor JJ. Serotonin and psychiatric disorders. Int Clinical Psychopharm. 1992; 7(2): 5-11.

400. Thomas DE, et al. Tryptophan and nutritional status in patients with senile dementia, Psychological Med. 1986; 16: 297-305.

401. Dr. Clark Information Center.

402. Du Bois C, Lubecki J. The End of Cancer. Nelson’s Books; 2003.

403. Curezone. Dental-cancer risk.

404. Haut MW, Morrow LA, Pool D, Callahan TS, Haut JS, Franzen MD. Neurobehavioral effects of acute exposure to inorganic mercury vapor. Appl Neuropsychol. 1999; 6(4): 193-200.

405. Rojas M, Olivet C. Occupational exposure and health effects of metallic mercury among dentists and dental assistants: a preliminary study. Acta Cient Venez. 2000; 51(1): 32-8.

406. Nadorfy-Lopez E, Bello B. Skeletal muscle abnormalities associated with occupational exposure to mercury vapors. Histol Histopathol. 2000; 15(3): 673-82.

407. Kang JH, Eum WS. Enhanced oxidative damage by the familial amyotrophic lateral sclerosis-associated Cu, Zn-superoxide dismutase mutants. Biochem Biophys Acta. 2000; 1524(2-3): 162-70.

408. Liu H, Zhu H, Eggers DK, Nersissian AM, et al. Copper(2+) binding to the surface residue cysteine 111 of His46Arg human copper-zinc superoxide dismutase, a familial amyotrophic lateral sclerosis mutant. Biochemistry. 2000; 39(28): 8125-32.

409. Wong PC, Gitlin JD, et al. Copper chaperone for superoxide dismutase is essential to activate mammalian Cu/Zn superoxide dismutase. Proc Natl Acad Sci, USA. 2000; 97(6): 2886-91.

410. Kruman II, Pedersen WA, Springer JE, Mattson MP. ALS-linked Cu/Zn-SOD mutation increases vulnerability of motorneurons to excitotoxicity by a mechanism involving increased oxidative stress and perturbed calcium homeostasis. Exp Neurol. 1999; 160(1): 28-39.

411. Doble A. The role of excitotoxicity in neurodegenerative disease: implications for therapy. Pharmacol Ther. 1999; 81(3): 163-221.

412. Urushitani M, Shimohama S. N-methyl-D-aspartate receptor-mediated mitochondrial Ca(2+) overload in acute excitotoxic motor neuron death: a mechanism distinct from chronic neurotoxicity after Ca(2+) influx. J Neurosci Res. 2001; 63(5): 377-87.

413. Cookson MR, Shaw PJ. Oxidative stress and motor neurons disease. Brain Pathol. 1999; 9(1): 165-86.

414. Torres-Aleman I, Barrios V, Berciano J. The peripheral insulin-like growth factor system in amyotrophic lateral sclerosis and in multiple sclerosis. Neurology. 1998; 50(3): 772-6.

415. Dall R, Sonksen PH, et al; The effect of four weeks of supraphysiological growth hormone administration on the insulin-like growth factor axis in women and men. GH-2000 Study Group. J Clin Endocrinol Metab. 2000; 85(11): 4193-200.

416. Pons S, Torres-Aleman I. Insulin-like growth factor-I stimulates dephosphorylation of ikappa B through the serine phosphatase calcineurin. J Biol Chem. 2000; 275(49): 38620-5.

417. Lai EC, Rudnicki SA. Effect of recombinant human insulin-like growth factor-I on progression of ALS. A placebo-controlled study. Neurology. 1997; 49(6): 1621-30.

418. Yuen EC, Mobley WC. Therapeutic applications of neurotrophic factors in disorders of motor neurons and peripheral nerves. Mol Med Today. 1995; 1(6): 278-86.

419. Dore S, Kar S, Quirion R. Rediscovering an old friend, IGF-I: Potential use in the treatment of neurodegenerative diseases. Trends Neurosci. 1997; 20(8): 326-31.

420. Couratier P, Vallat JM. Therapeutic effects of neurotrophic factors in ALS. Rev Neurol (Paris). 2000; 156(12): 1075-7.

421. Guermonprez L, Ducrocq C, Gaudry-Talarmain YM. Inhibition of acetylcholine synthesis and tyrosine nitration induced by peroxynitrite is differentially prevented by antioxidants. Mol Pharmacol. 2001; 60(4): 838-46.

422. Mahboob M, Shireen KF, Atkinson A, Khan AT. Lipid peroxidation and antioxidant enzyme activity in different organs of mice exposed to low level of mercury. J Environ Sci Health B. 2001; 36(5): 687-97.

423. Urushitani M, Shimohama S. The role of nitric oxide in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord. 2001; 2(2): 71-81.

424. Torreilles F, Salman-Tabcheh S, Guerin M, Torreilles J. Neurodegenerative disorders: the role of peroxynitrite. Brain Res Brain Res Rev. 1999; 30(2): 153-63.

425. Aoyama K, Matsubara K, Kobayashi S. Nitration of manganese superoxide dismutase in cerebrospinal fluids is a marker for peroxynitrite-mediated oxidative stress in neurodegenerative diseases. Ann Neurol. 2000; 47 (4): 524-7.

426. Cheshire, William P. The shocking tooth about trigeminal neuralgia. New England Journal of Medicine. 2003; 342.

427. Bergman M, Ginstrup O, Nilsson B. Potentials of and currents between dental metallic restorations. Scand J Dent Res. 1982; 90: 404-8.

428. Hugoson A. Results obtained from patients referred for the investigation of complaints related to oral galvanism. Swed Dent J. 1986; 10: 15-28.

429. Muller AW, Van Loon LA, Davidson CL. Electrical potentials of restorations in subjects without oral complaints. J Oral Rehabil. 1990; 17: 419-24.

430. Raue H. Resistance to therapy: Think of tooth fillings. Medical Practice. 1980; 32(72): 2303- 2309.

431. Tirado V, Garcia MA, Franco A. Pneuropsychological disorders after occupational exposure to mercury vapors. Rev Neurol 2000; 31(8): 712-6.

432. Powell TJ. Chronic neurobehavioural effects of mercury poisoning on a group of chemical workers. Brain Inj. 2000; 14(9): 797-814.

433. Mercola J. Learn how mercury is affecting you and the ones you love.

434. Lindh U, Hudecek R, Danersund A, Eriksson S, Lindvall A. Removal of dental amalgam and other metal alloys supported by antioxidant therapy alleviates symptoms and improves quality of life in patients with amalgam-associated ill health. Neuroendocrinology Letters. 2002; 23(5-6): 459-82.

435. Lewis RN, Bowler K. Rat brain (Na+-K+)ATPase: Modulation of its ouabain-sensitive K+-PNPPase activity by thimerosal. Int J Biochem. 1983; 15(1): 5-7.

436. Bellabarba D, Tremblay R. Effect of thimerosal on serum binding of thyroid hormones. Can J Physsiol Pharmacol. 1973; 51: 156-159.

437. Hokkfen B, Kodding R, Hesch RD. Regulation of thyroid hormone metabolism in rat liver fractions. Biochim Biophys Acta. 1978; 539(1): 114-24.

438. Uversky VN, Li J, Fink AL. Metal-triggered structural transformations, aggregation, and fibrillation of human alpha-synuclein. A possible molecular link between Parkinson’s disease and heavy metal exposure. J Biol Chem. 2001; 276(47): 44284-96.

439. Beuter A, de Geoffroy A, Edwards R. Quantitative analysis of rapid pointing movements in Cree subjects exposed to mercury and in subjects with neurological deficits. Environ Res. 1999; 80(1): 50-63.

440. Cesarani A, Minoia C, Pigatto PD, Guzzi G. Mercury, dental amalgam, and hearing loss. Int J Audiol. 2010; 49(1): 69-70.

441. Pritchard C, et al. Pollutants appear to be the cause of the huge rise in degenerative neurological conditions. Public Health. 2004.

442. Mutter J, et al. Alzheimer’s disease: Mercury as pathogenetic factor and apolipoprotein E as a moderator. Neuroendocrinology Letters. 2004; 25(5): 331-339.

443. Mutter J, Daschner F, et al. Amalgam risk assessment with coverage of references up to 2005. Gesundheitswesen. 2005; 67(3): 204-16.

444. Klinghardt D, Mercola J. Mercury toxicity and systemic elimination agents. J of Nutritional and Environmental Medicine. 2001; 11: 53-62.

445. Kidd RF. Results of dental amalgam removal and mercury detoxification using DMPS and neural therapy. Alternative Therapies. 2000; 6(4): 49-55.

446. Sircus. Aluminum hydroxide. 2009.

447. Cave S, Mitchell D. What Your Doctor May Not Tell You about Children’s Vaccinations. Warner Books; 2001.

448. Waly M, et al. Activation of methionine synthase by insulin-like growth factor-1 and dopamine: A target for neurodevelopmental toxins and thimerosal. Molecular Psychiatry. 2004: 1-13.

Print Friendly